Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-Label, Phase IIIb Trial of Tarceva (Erlotinib Hydrochloride) in Patients With Advanced Non-Small Cell Lung Cancer

NCT00091663 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT00091663
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00091663 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-Label, Phase IIIb Trial of Tarceva (Erlotinib Hydrochloride) in Patients With Advanced Non-Small Cell Lung Cancer
Lead sponsor
Genentech, Inc.
Phase
Phase 3
Overall status
Completed
Start date
August 31, 2004
Completion date
August 31, 2005
Enrollment
5,000
Sites
92

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer, non-small-cell lung carcinoma